• Jordi Río, Alex Rovira, Mar Tintoré, Jaume Sastre-Garriga, Joaquín Castilló, Cristina Auger, Carlos Nos, Manuel Comabella, Carmen Tur, Ángela Vidal, and Xavier Montalbán.
• Centre d'esclerosi múltiple de Catalunya (CEM-Cat), Servei de Neurologia-Neuroimmunologia, Hospital Universitario Vall d'Hebron, Barcelona, Spain jrio@vhebron.net.
• Mult. Scler. 2014 Oct 1; 20 (12): 1602-8.

BackgroundIn patients with relapsing-remitting multiple sclerosis (RRMS), a scoring system based on new magnetic resonance imaging (MRI) active lesions, relapses and sustained disability progression after a 1-year treatment with IFNβ predicted patient disability progression over time; however, this score had not been tested in patients receiving glatiramer acetate (GA).ObjectiveThe objective of this study was to evaluate whether this previous scoring system can also be applied to patients treated with GA.MethodsThis was a prospective, longitudinal study of 151 RRMS patients treated with GA. Their scores were constructed, based on the clinical and MRI activity after 1 year of therapy. Regression analysis was performed, in order to identify the response variables.ResultsThe total possible score range was 0-3. Patients with a score of ≥ 2 and those with clinical activity (with or without MRI activity) during their first year of treatment were at increased risk of continuing with relapses and/or sustained disability in the next 2 years (odds ratio (OR): 38.8; p < 0.0001 and OR: 7.8; p < 0.009, respectively).ConclusionsIn RRMS patients treated with GA, a combination of clinical activity measures may have prognostic value for identifying patients with disease activity in the next 2 years of therapy.© The Author(s) 2014.

32 keywords...

hide…